Breast Tumors with Elevated Expression of 1q Candidate Genes Confer Poor Clinical Outcome and Sensitivity to Ras/PI3K Inhibition

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Muthuswami, Muthulakshmi ^a   Ramesh, Vignesh ^a   Banerjee, Saikat ^a   Viveka Thangaraj, Soundara ^a   Periasamy, Jayaprakash ^a   Bhaskar Rao, Divya ^a   Barnabas, Georgina D ^a   Raghavan, Swetha ^b   Ganesan, Kumaresan ^a  

^a MADURAI KAMARAJ UNIVERSITY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EXONUCLEASE; EXONUCLEASE 1; MESSENGER RNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME 1; CHROMOSOME ABERRATION; CONTROLLED STUDY; COPY NUMBER VARIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FUNCTIONAL GENOMICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOCUS; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; OPEN READING FRAME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PROMOTER REGION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMONES; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 1; CLUSTER ANALYSIS; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; E2F TRANSCRIPTION FACTORS; EXODEOXYRIBONUCLEASES; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MORPHOLINES; NEOPLASM GRADING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); QUANTITATIVE TRAIT LOCI; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84885750364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077553     Document Type: Article

References (68)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752. doi:10.1038/35021093. PubMed: 10963602.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc_Natl_Acad_Sci_U_S_A 98: 10869-10874. PubMed: 11553815.
3. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536. doi:10.1038/415530a. PubMed: 11823860.
4. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet %19-25;365: 671-679.
5. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc_Natl_Acad_Sci_U_S_A 101: 9309-9314. PubMed: 15184677.
6. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, et al. (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65. doi:10.1186/bcr1949. PubMed: 18662380.
7. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, et al. (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLOS_ONE 4: e6146. PubMed: 19582160.
8. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527. doi:10.1016/j.ccr.2006.10.008. PubMed: 17157791.
9. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352. PubMed: 22522925.
10. Atkin NB, (1986) Chromosome 1 aberrations in cancer. Cancer Genet_Cytogenet 21: 279-285. PubMed: 3513945.
11. Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, et al. (2006) Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q. BrJCancer %20;95: 1439-1447.
12. Fang M, Toher J, Morgan M, Davison J, Tannenbaum S, et al. (2011) Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis. Cancer 117: 2024-2034. doi:10.1002/cncr.25770. PubMed: 21523713.
13. Waddell N, Arnold J, Cocciardi S, da SL, Marsh A, et al. (2010) Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res_Treat 123: 661-677. doi:10.1007/s10549-009-0653-1. PubMed: 19960244.
14. Gao Y, Niu Y, Wang X, Wei L, Lu S, (2009) Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. JMolMed(Berl) 87: 145-152.
15. Bièche I, Champème MH, Lidereau R, (1995) Loss and gain of distinct regions of chromosome 1q in primary breast cancer. Clin_Cancer Res 1: 123-127. PubMed: 9815894.
16. Stange DE, Radlwimmer B, Schubert F, Traub F, Pich A, et al. (2006) High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin_Cancer Res 12: 345-352. PubMed: 16428471.
17. Farabegoli F, Hermsen MA, Ceccarelli C, Santini D, Weiss MM, et al. (2004) Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma. Mod_Pathol 17: 449-455. PubMed: 14976537.
18. Albertson DG, Collins C, McCormick F, Gray JW, (2003) Chromosome aberrations in solid tumors. Nat_Genet 34: 369-376. PubMed: 12923544.
19. T T (2012). A Package Surviv Anal S.
20. Therneau M, [!(surname)!], Grambsch M P, (2000) Modeling Survival Data: Extending the Cox Model: Springer Verlag.
21. Fox J, (2005) The R Commander: A Basic Statistics Graphical User Interface to R. J Stat Softw 14: 1-42.
22. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504. doi:10.1101/gr.1239303. PubMed: 14597658.
23. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, et al. (2009) Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLOS_Genet 5: e1000676. PubMed: 19798449.
24. Kim TM, Jeong HJ, Seo MY, Kim SC, Cho G, et al. (2005) Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. Clin Cancer Res 11: 79-86. PubMed: 15671531.
25. Dyer BW, Ferrer FA, Klinedinst DK, Rodriguez R, (2000) A noncommercial dual luciferase enzyme assay system for reporter gene analysis. Anal_Biochem 282: 158-161. PubMed: 10860516.
26. Caron H, van SB, van der Mee M, Baas F, Riggins G, et al. (2001) The human transcriptome map: clustering of highly expressed genes in chromosomal domains. Science 291: 1289-1292. doi:10.1126/science.1056794. PubMed: 11181992.
27. O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, et al. (2007) CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int_J_Cancer 120: 1434-1443. PubMed: 17205517.
28. Corson TW, Gallie BL, (2006) KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int_J_Cancer 119: 1088-1094. PubMed: 16570270.
29. Tsunoda N, Kokuryo T, Oda K, Senga T, Yokoyama Y, et al. (2009) Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Sci 100: 111-116. doi:10.1111/j.1349-7006.2008.01007.x. PubMed: 19038001.
30. Ueki T, Nishidate T, Park JH, Lin ML, Shimo A, et al. (2008) Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene 27: 5672-5683. doi:10.1038/onc.2008.186. PubMed: 18542055.
31. Wang XC, Tian J, Tian LL, Wu HL, Meng AM, et al. (2009) Role of Cks1 amplification and overexpression in breast cancer. BiochemBiophysResCommun %20;379: 1107-1113.
32. Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, et al. (2006) Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc_Natl_Acad_Sci_U_S_A 103: 17402-17407. PubMed: 17090670.
33. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, et al. (2011) Identification of early molecular markers for breast cancer. Mol_Cancer 10: 15-10. PubMed: 21314937.
34. Wang HC, Chiu CF, Tsai RY, Kuo YS, Chen HS, et al. (2009) Association of genetic polymorphisms of EXO1 gene with risk of breast cancer in Taiwan. Anticancer Res 29: 3897-3901. PubMed: 19846925.
35. Luo X, Hong XS, Xiong XD, Zeng LQ, Lim CE, (2012) A single nucleotide polymorphism in EXO1 gene is associated with cervical cancer susceptibility in Chinese patients. Int_J_Gynecol_Cancer 22: 220-225. PubMed: 22146767.
36. Bau DT, Wang HC, Liu CS, Chang CL, Chiang SY, et al. (2009) Single-nucleotide polymorphism of the Exo1 gene: association with gastric cancer susceptibility and interaction with smoking in Taiwan. Chin JPhysiol 52: 411-418. doi:10.4077/CJP.2009.AMH076. PubMed: 20337148.
37. Wei K, Clark AB, Wong E, Kane MF, Mazur DJ, et al. (2003) Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility. Genes Dev 17: 603-614. doi:10.1101/gad.1060603. PubMed: 12629043.
38. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935. doi:10.1126/science.1132939. PubMed: 17008526.
39. Schmutte C, Marinescu RC, Sadoff MM, Guerrette S, Overhauser J, et al. (1998) Human exonuclease I interacts with the mismatch repair protein hMSH2. Cancer Res 58: 4537-4542. PubMed: 9788596.
40. Fichtinger-Schepman AM, van Dijk-Knijnenburg HC, SD vdV-V, Berends F, Baan RA (1995) Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion? Carcinogenesis 16: 2447-2453.
41. Harrouk W, Codrington A, Vinson R, Robaire B, Hales BF, (2000) Paternal exposure to cyclophosphamide induces DNA damage and alters the expression of DNA repair genes in the rat preimplantation embryo. Mutat_Res 461: 229-241. PubMed: 11056294.
42. Korkmaz A, Topal T, Oter S, (2007) Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol_Toxicol 23: 303-312. PubMed: 17225077.
43. Fonseca FL, Sant Ana AV, Bendit I, Arias V, Costa LJ, et al. (2005) Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients. Breast Cancer Res 7: R28-R32. doi:10.1186/bcr1232. PubMed: 15642167.
44. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc_Natl_Acad_Sci_U_S_A 102: 15545-15550. PubMed: 16199517.
45. Wang S, Li W, Lv S, Wang Y, Liu Z, et al. (2011) Abnormal expression of Nek2 and beta-catenin in breast carcinoma: clinicopathological correlations. Histopathology 59: 631-642. doi:10.1111/j.1365-2559.2011.03941.x. PubMed: 22014044.
46. Hagemann C, Anacker J, Gerngras S, Kühnel S, Said HM, et al. (2008) Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas. Oncol_Rep 20: 301-308. PubMed: 18636190.
47. Downward J, (2003) Targeting RAS signalling pathways in cancer therapy. Nat_Rev_Cancer 3: 11-22. PubMed: 12509763.
48. Eckert LB, Repasky GA, Ulkü AS, McFall A, Zhou H, et al. (2004) Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 64: 4585-4592. doi:10.1158/0008-5472.CAN-04-0396. PubMed: 15231670.
49. Castellano E, Downward J, (2011) RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer 2: 261-274. doi:10.1177/1947601911408079. PubMed: 21779497.
50. Schild C, Wirth M, Reichert M, Schmid RM, Saur D, et al. (2009) PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells. Mol_Carcinog 48: 1149-1158. PubMed: 19603422.
51. Berkovich E, Ginsberg D, (2001) Ras induces elevation of E2F-1 mRNA levels. Biol_Chem 276: 42851-42856. PubMed: 11551910.
52. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, et al. (2009) Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol_Cancer Res 7: 511-522. PubMed: 19372580.
53. Melchor L, Benítez J, (2008) An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. Carcinogenesis 29: 1475-1482. doi:10.1093/carcin/bgn157. PubMed: 18596026.
54. Desmedt C, Sotiriou C, (2006) Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle 5: 2198-2202. doi:10.4161/cc.5.19.3254. PubMed: 16969100.
55. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, et al. (2007) Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res 67: 3320-3328. doi:10.1158/0008-5472.CAN-06-4287. PubMed: 17409441.
56. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, et al. (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLOS_Biol 2: E7. PubMed: 14737219.
57. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z, (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat_Genet 38: 1043-1048. PubMed: 16921376.
58. Engelman JA, (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat_Rev_Cancer 9: 550-562. PubMed: 19629070.
59. Hobday TJ, Perez EA, (2005) Molecularly targeted therapies for breast cancer. Cancer Contr 12: 73-81. PubMed: 15855890.
60. Lièvre A, Bachet JB, Le CD, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995. doi:10.1158/0008-5472.CAN-06-0191. PubMed: 16618717.
61. Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bündgen NK, et al. (2009) The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int_J_Cancer 124: 1552-1564. PubMed: 19101988.
62. Ghazani AA, Arneson N, Warren K, Pintilie M, Bayani J, et al. (2007) Genomic alterations in sporadic synchronous primary breast cancer using array and metaphase comparative genomic hybridization. Neoplasia 9: 511-520. doi:10.1593/neo.07301. PubMed: 17603634.
63. Park SC, Hwang UK, Ahn SH, Gong GY, Yoon HS, (2007) Genetic changes in bilateral breast cancer by comparative genomic hybridisation. Clin_Exp_Med 7: 1-5. PubMed: 17380298.
64. Karlsson E, Danielsson A, Delle U, Olsson B, Karlsson P, et al. (2007) Chromosomal changes associated with clinical outcome in lymph node-negative breast cancer. Cancer Genet_Cytogenet 172: 139-146. PubMed: 17213022.
65. Gronwald J, Jauch A, Cybulski C, Schoell B, Böhm-Steuer B, et al. (2005) Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization. Int_J_Cancer, 114: 230-6 %20;114: 230-236 PubMed: 15540206.
66. Weber-Mangal S, Sinn HP, Popp S, Klaes R, Emig R, et al. (2003) Breast cancer in young women (< or = 35 years): Genomic aberrations detected by comparative genomic hybridization. Int_J_Cancer, 107: 583-92 %20;107: 583-592 PubMed: 14520696.
67. Baudis M, Cleary ML, (2001) Progenetix. net: an online repository for molecular cytogenetic aberration data. Bioinformatics 17: 1228-1229. doi:10.1093/bioinformatics/17.12.1228. PubMed: 11751233.
68. Baudis M, (2012) Progenetix oncogenomic online resource. Retrieved onpublished at whilst December year 1111 from www.progenetix.net.